LCM
PCVX icon

Legato Capital Management’s Vaxcyte PCVX Stock Holding History

Legato Capital Management’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.26M Buy
+21,645
New +$1.18M 0.1% 292
2025
Q2 		– Sell
-10,823
Closed -$409K – 604
2025
Q1 		$409K Buy
10,823
+1,818
+20% +$145K 0.06% 452
2024
Q4 		$737K Sell
9,005
-2,627
-23% -$261K 0.1% 371
2024
Q3 		$1.33M Buy
11,632
+613
+6% +$55.2K 0.16% 218
2024
Q2 		$832K Buy
11,019
+3,010
+38% +$205K 0.11% 307
2024
Q1 		$547K Sell
8,009
-4,187
-34% -$290K 0.07% 422
2023
Q4 		$766K Buy
12,196
+1,498
+14% +$77.8K 0.1% 324
2023
Q3 		$545K Sell
10,698
-9,210
-46% -$454K 0.08% 381
2023
Q2 		$994K Buy
19,908
+13,383
+205% +$634K 0.13% 262
2023
Q1 		$245K Buy
6,525
+2,334
+56% +$99K 0.04% 429
2022
Q4 		$201K Buy
+4,191
New +$164K 0.04% 453

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Legato Capital Management's PCVX Position: Q2 2026 in Review

Legato Capital Management opened a new position in Vaxcyte (PCVX) in Q2 2026: 21,645 shares worth $1.26M. The stake represents 0.1% of the portfolio and ranks #292 among its holdings. This is a return to the name: Legato Capital Management previously reported a position in PCVX as recently as Q1 2025.

Legato Capital Management first reported a position in PCVX in Q4 2022 and has held it in 11 quarters since. The position peaked at $1.33M in Q3 2024. 331 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

  • Legato Capital Management held 21,645 shares of Vaxcyte worth $1.26M as of Q2 2026.
  • Vaxcyte was a new Legato Capital Management position in Q2 2026.
  • Vaxcyte made up 0.1% of Legato Capital Management's portfolio in Q2 2026, its #292 holding.
  • Legato Capital Management first reported a position in Vaxcyte in Q4 2022 and has held it in 11 quarters since.
  • Legato Capital Management's Vaxcyte position peaked at $1.33M in Q3 2024.
  • 331 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on Legato Capital Management's 13F filing for Q2 2026, filed 6 Aug 2026.